Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP982530priorityCriticalpatent/ECSP982530A/en
Publication of ECSP982530ApublicationCriticalpatent/ECSP982530A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
Se describen novedosos compuestos de sulfonamida y composiciones farmacéuticas que son inhibidores de la enzina proteína transferasa. También se describe un método para inhibir la función Ras y, por lo tanto, para inhibir el desarrollo anormal de las células. El método consiste en administrar el novedoso compuesto de sulfonamida a un sistema biológico. Específicamente, el método inhibe el desarrollo anormal de las células en mamíferos tales como seres humanos.Novel sulfonamide compounds and pharmaceutical compositions that are inhibitors of the protein transferase enzyme are described. Also described is a method of inhibiting Ras function and, therefore, of inhibiting abnormal cell development. The method is to administer the novel sulfonamide compound to a biological system. Specifically, the method inhibits abnormal cell development in mammals such as humans.
ECSP9825301998-06-151998-06-15
NOVEL SULFONAMIDE INHIBITORS FROM FARNESIL - PROTEIN TRANSFERASA
ECSP982530A
(en)
at least one chemical entity, pharmaceutical composition, methods for treating a patient, inhibiting at least one enzyme using atp, and treating at least one disease, use of at least one chemical entity, and method for the manufacture of a medicament
2-OPTICALLY ACTIVE AMINOTETRALINE, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT, ACTIVE IN THE PREVENTION AND TREATMENT OF SEPTIC SHOCK.
APPLICATION OF HCG (HUMAN GONADOTROPHINACORIONICA), BETA SUBUNITS, ACTIVE FRAGMENTS AND DERIVED FROM THEM AS INHIBITORS OF METALLOPROTEIN MATRICES AND PHARMACEUTICAL COMPOSITIONS INCLUDING SUCH INHIBITORS